RAYDIAX Raises €7.5M to Advance Therapy CT in Oncology
French medtech company RAYDIAX has secured a €7.5 million funding round to trial its next‑generation therapy CT scanner within real‑world oncology workflows. The investment is aimed at validating how advanced imaging can be tightly integrated into daily cancer treatment, particularly for radiotherapy and interventional oncology.
Embedding Imaging Directly Into Cancer Treatment
RAYDIAX is developing a therapy-focused computed tomography platform designed to sit at the heart of the treatment room rather than being used solely for diagnostic imaging. By combining high‑precision CT imaging with treatment planning and delivery, the system seeks to give clinicians real‑time visibility of tumors and surrounding organs at risk.
The new funding will support clinical trials that evaluate how the scanner performs when integrated into existing radiotherapy and interventional oncology pathways. The goal is to reduce uncertainties in patient positioning, adapt treatment to anatomical changes, and potentially lower side effects by improving dose targeting.
Improving Accuracy and Efficiency in Oncology Workflows
Oncology departments often rely on separate systems for imaging, planning, and treatment delivery, leading to fragmented data and time‑consuming workflows. RAYDIAX aims to streamline these steps by enabling continuous imaging before, during, and after therapy sessions.
By embedding the therapy CT scanner into the workflow, clinicians could verify tumor position on the table, adapt plans on the fly, and document treatment response with greater precision. This approach aligns with the broader shift toward personalised medicine and image‑guided radiation therapy.
Backing for Next‑Generation Medtech Innovation
The €7.5 million round underscores investor confidence in advanced medical imaging technologies that promise both clinical and operational benefits. Funds will be used to complete technical validation, run multi‑centre trials, and prepare for regulatory submissions in key markets.
If successful, RAYDIAX‘s therapy CT platform could become a core component of modern cancer centres, helping oncologists deliver safer, more accurate treatments while improving patient throughput and data quality.